Topics
High-grade gliomas | Treatment | Targeted therapy | Bevacizumab
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Bevacizumab
Liao Y, Bai X, Cao Y, Zhang
M.
Effect
of low-dose bevacizumab on health-related quality of life in
patients with recurrent high-grade glioma: A retrospective
clinical study.
J
Clin Neurosci.
2024 Jan 25;120:196-203. doi: 10.1016/j.jocn.2024.01.018? PMID:
38277995. Observational study. ˍ
Bai X, Xing H, Feng M, Ma W, Wang S.
Dose
and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A
Retrospective Study.
Cancer
Manag Res. 2024 Nov 16;16:1617-1626. doi:
10.2147/CMAR.S481289. PMID:
39575164. Observational study. ˍ
Henriksen OM, Maarup S, Hasselbalch B, Poulsen HS, Christensen IJ,
Madsen K, Larsen VA, Lassen U, Law I.
Magnetic
resonance imaging and
o-(2-[18F]fluoroethyl)-l-tyrosine
positron emission tomography for
early response assessment of
nivolumab and bevacizumab in patients with
recurrent high-grade astrocytic
glioma.
Neurooncol
Adv. 2024 Oct 24;6(1):vdae178. doi:
10.1093/noajnl/vdae178. PMID:
39659835. Interventional study. ˍ